Zobrazeno 1 - 10
of 13
pro vyhledávání: '"WILLIAM A.E. PARKER"'
Publikováno v:
Platelets, Vol 34, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/fbcec1be27024b6d9c2eafe2c56e5d62
Autor:
Thomas A. Nelson, William A.E. Parker, Tatevik Ghukasyan Lakic, Johan Westerbergh, Stefan K. James, Agneta Siegbahn, Richard C. Becker, Anders Himmelmann, Lars Wallentin, Robert F. Storey
Publikováno v:
Platelets, Vol 33, Iss 3, Pp 425-431 (2022)
Inflammation plays a key role in cardiovascular disease by contributing to atherothrombosis. The PLATelet inhibition and patient Outcomes (PLATO) study (NCT00391872) compared ticagrelor to clopidogrel in patients with acute coronary syndromes and dem
Externí odkaz:
https://doaj.org/article/3426b1c0b4de42d8a6bd4a88f7a209d4
Autor:
Barry W. Hennigan, Richard Good, Carly Adamson, William A.E. Parker, Lynn Martin, Lynne Anderson, Michael Campbell, Patrick W. Serruys, Robert F. Storey, Keith G. Oldroyd
Publikováno v:
Platelets, Vol 33, Iss 1, Pp 141-146 (2022)
Cessation of one component of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has been associated with increased risk of ischemic events but it is uncertain whether discontinuation of aspirin is preferable to disco
Externí odkaz:
https://doaj.org/article/aa35e867f6c74636a423997017f00e77
Autor:
Wael Sumaya, William A.E. Parker, Heather M. Judge, Ian R. Hall, Rachel C. Orme, Zulfiquar Adam, James D. Richardson, Alexander M.K. Rothman, Kenneth P. Morgan, Julian P. Gunn, Robert F. Storey
Publikováno v:
Platelets, Vol 32, Iss 4, Pp 555-559 (2021)
A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intravenous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed absorption of oral P2Y12 inhibitors in opiate-treated ST-elevati
Externí odkaz:
https://doaj.org/article/3333115ba44f4ecd927f58c21aa5c9b6
Autor:
Kok Weng Ow, William A.E. Parker, Mark M. Porter, Jessica Hanson, Heather M. Judge, Norman P. Briffa, Mark R. Thomas, Robert F. Storey
Publikováno v:
Platelets, Vol 31, Iss 7, Pp 945-951 (2020)
Ticagrelor is an antagonist of both platelet adenosine diphosphate (ADP) receptor P2Y12 and equilibrative nucleoside transporter-1. Optimal timing of ticagrelor cessation prior to coronary artery bypass grafting (CABG) remains unclear. We characteriz
Externí odkaz:
https://doaj.org/article/6679e36a3a2e4e2797306c0e383e84d4
Autor:
William A.E. Parker, Rachel C. Orme, Jessica Hanson, Hannah M. Stokes, Claire M. Bridge, Patricia A. Shaw, Wael Sumaya, Kirstie Thorneycroft, Giovanna Petrucci, Benedetta Porro, Heather M. Judge, Ramzi A. Ajjan, Bianca Rocca, Robert F. Storey
Publikováno v:
Platelets, Vol 30, Iss 2, Pp 148-157 (2019)
Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We characterized the pharmacodynamics of a novel dual-anti
Externí odkaz:
https://doaj.org/article/b985dd267bf043f095a2e15eab57596f
Autor:
Robert F. Storey, William A.E. Parker
Publikováno v:
Journal of the American College of Cardiology. 81:1933-1936
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51f7f9edc96dda4bb92532ec4a1c1839
https://doi.org/10.1016/j.jacc.2023.03.391
https://doi.org/10.1016/j.jacc.2023.03.391
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Trace amine-associated receptors were discovered from a search for novel 5-HT receptors [9], where 15 mammalian orthologues were identified and divided into two families. The TA1 receptor (nomenclature as agreed by the NC-IUPHAR Subcommittee for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc0d9e8986b1f884ea31b450ca8ed485
https://doi.org/10.2218/gtopdb/f64/2023.1
https://doi.org/10.2218/gtopdb/f64/2023.1
Autor:
ALEKSANDER SINIARSKI, ALEKSANDRA GĄSECKA, JOSIP ANDELO BOROVAC, PANTELEIMON E. PAPAKONSTANTINOU, DARIO BONGIOVANNI, HANNE EHRLINDER, MICHELA GIUSTOZZI, RUI AZEVEDO GUERREIRO, WILLIAM A.E. PARKER
Heart failure (HF) is a clinical syndrome divided into three subtypes, based on the left ventricular ejection fraction. Every subtype has specific clinical characteristics and concomitant diseases, substantially increasing risk of thromboembolic comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87843b26a7a3529e050a55d76e23e79a
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/100886
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/100886
Autor:
Robert A. Ariëns, Beverley J. Hunt, Ejaife O. Agbani, Josefin Ahnström, Robert Ahrends, Raza Alikhan, Alice Assinger, Zsuzsa Bagoly, Alessandra Balduini, Elena Barbon, Christopher D. Barrett, Paul Batty, Jorge David Aivazoglou Carneiro, Wee Shian Chan, Moniek de Maat, Kerstin de Wit, Cécile Denis, Martin H. Ellis, Renee Eslick, Hongxia Fu, Catherine P.M. Hayward, Benoit Ho‐Tin‐Noé, Frederikus A. Klok, Riten Kumar, Karin Leiderman, Rustem I. Litvinov, Nigel Mackman, Zoe McQuilten, Matthew D. Neal, William A.E. Parker, Roger J.S. Preston, Julie Rayes, Alireza R. Rezaie, Lara N. Roberts, Bianca Rocca, Susan Shapiro, Deborah M. Siegal, Lirlândia P. Sousa, Katsue Suzuki‐Inoue, Tahira Zafar, Jiaxi Zhou
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, 6(5). WILEY
Research and Practice in Thrombosis and Haemostasis, 6(5):e12747. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 6(5):e12747. Wiley-Blackwell Publishing Ltd
The ISTH London 2022 Congress is the first held (mostly) face-to-face again since the COVID-19 pandemic took the world by surprise in 2020. For 2 years we met virtually, but this year’s in-person format will allow the ever-so-important and quintess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aafeeac104084dcf5a6c5a4d6d3c9405
http://hdl.handle.net/1887/3566928
http://hdl.handle.net/1887/3566928